ReviewACR open rheumatology2021
Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases.
Review in ACR open rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Patient reports of evaluations for interstitial lung disease in patients with connective tissue diseases and rheumatoid arthritis: an international survey.Respiratory research · 2026Article
- Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease.Journal of clinical medicine · 2026Article
- Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.The clinical respiratory journal · 2025Review
- Evaluating the diagnostic and prognostic utility of serial KL-6 measurements in connective tissue disease patients at risk for interstitial lung disease: correlations with pulmonary function tests and high-resolution computed tomography.BMC pulmonary medicine · 2024Article
- Progressive pulmonary fibrosis in patients with connective tissue disease-associated interstitial lung disease: An explorative study.Archives of rheumatology · 2024Article
- Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study.Clinical rheumatology · 2023Observational
- Management of interstitial lung disease in patients with autoimmune disease-related interstitial lung disease.Multidisciplinary respiratory medicine · 2023Article
- Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease.Case reports in pulmonology · 2022Article
- Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders.Therapeutic advances in musculoskeletal disease · 2021Review
- Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada.Journal of cutaneous medicine and surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Interstitial lung disease (ILD) is a common manifestation of connective tissue diseases (CTDs). A proportion of patients with CTD-ILDs develop progressive fibrosing ILD, which is characterized by worsening fibrotic abnormalities on high-resolution computed tomography scan, decline in lung function, worsening symptoms, and early mortality. Here, we review the impact of ILD in patients with CTDs, the importance of prompt diagnosis and close monitoring, and the evidence available to guide the management of CTD-ILDs. Management of patients with CTD-ILDs should be individualized and involve close collaboration between rheumatologists and pulmonologists. Immunosuppression is the mainstay of therapy for CTDs, but evidence for its effectiveness in slowing the progression of ILD is limited. Recently, nintedanib has been approved to slow decline in lung function in patients with systemic sclerosis-associated ILD and chronic fibrosing ILDs with a progressive phenotype. The results of ongoing clinical trials will help clinicians take a more evidence-based approach to the treatment of CTD-ILDs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.